Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1600-1609

  Ansó, Elena ^a   Zuazo, Alicia ^a   Irigoyen, Marta ^b   Urdaci, María C ^c   Rouzaut, Ana ^b   Martínez Irujo, Juan J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; Flavonoids; HIF; Hypoxia; STAT3; VEGF

Indexed keywords

4,7 DIHYDROXIFLAVONE; APIGENIN; EPIDERMAL GROWTH FACTOR; FISETIN; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; GALANGIN; HISTONE ACETYLTRANSFERASE PCAF; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOFLAVONE DERIVATIVE; LUTEOLIN; QUERCETIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL LEVEL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG HYDROXYLATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 77950089188     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.004     Document Type: Article

References (41)

1. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 2008, 52:507-526.
2. Osada M., Imaoka S., Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett 2004, 575:59-63.
3. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., Jiang B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005, 19:342-353.
4. Liu L.Z., Fang J., Zhou Q., Hu X., Shi X., Jiang B.H. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 2005, 68:635-643.
5. Zhang Q., Tang X., Lu Q.Y., Zhang Z.F., Brown J., Le A.D. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005, 4:1465-1474.
6. Fang J., Zhou Q., Liu L.Z., Xia C., Hu X., Shi X., et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007, 28:858-864.
7. Fu B., Xue J., Li Z., Shi X., Jiang B.H., Fang J. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther 2007, 6:220-226.
8. Park S.Y., Jeong K.J., Lee J., Yoon D.S., Choi W.S., Kim Y.K., et al. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett 2007, 258:63-69.
9. Mirzoeva S., Kim N.D., Chiu K., Franzen C.A., Bergan R.C., Pelling J.C. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinogen 2008, 47:686-700.
10. Bagli E., Stefaniotou M., Morbidelli L., Ziche M., Psillas K., Murphy C., et al. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 2004, 64:7936-7946.
11. Buchler P., Reber H.A., Buchler M.W., Friess H., Lavey R.S., Hines O.J. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 2004, 100:201-210.
12. Powis G., Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004, 3:647-654.
13. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
14. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
15. Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M., Wagner G., et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A 2002, 99:5367-5372.
16. Gray M.J., Zhang J., Ellis L.M., Semenza G.L., Evans D.B., Watowich S.S., et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110-3120.
17. Emerling B.M., Weinberg F., Liu J.L., Mak T.W., Chandel N.S. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 2008, 105:2622-2627.
18. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 2006, 281:33095-33106.
19. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44.
20. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel-Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002, 277:29936-29944.
21. Liu Y.V., Semenza G.L. RACK1 vs HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell cycle 2007, 6:656-659.
22. Fontanini G., Vignati S., Boldrini L., Chine S., Silvestri V., Lucchi M., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861-865.
23. Cui Y., Morgenstern H., Greenland S., Tashkin D.P., Mao J.T., Cai L., et al. Dietary flavonoid intake and lung cancer-a population-based case-control study. Cancer 2008, 112:2241-2248.
24. Mursu J., Nurmi T., Tuomainen T.P., Salonen J.T., Pukkala E., Voutilainen S. Intake of flavonoids and risk of cancer in Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Int J Cancer 2008, 123:660-663.
25. Cutler G.J., Nettleton J.A., Ross J.A., Harnack L.J., Jacobs D.R., Scrafford C.G., et al. Dietary flavonoid intake and risk of cancer in postmenopausal women: the Iowa Women's Health Study. Int J Cancer 2008, 123:664-671.
26. Irigoyen M., Anso E., Martinez E., Garayoa M., Martinez-Irujo J.J., Rouzaut A. Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 2007, 1773:880-890.
27. Talorete T.P., Bouaziz M., Sayadi S., Isoda H. Influence of medium type and serum on MTT reduction by flavonoids in the absence of cells. Cytotechnology 2006, 52:189-198.
28. Triantafyllou A., Mylonis I., Simos G., Bonanou S., Tsakalof A. Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 2008, 44:657-670.
29. Li Y., Wang Z., Kong D., Li R., Sarkar S.H., Sarkar F.H. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem 2008, 283:27707-27716.
30. Sunters A., Madureira P.A., Pomeranz K.M., Aubert M., Brosens J.J., Cook S.J., et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 2006, 66:212-220.
31. Fath D.M., Kong X., Liang D., Lin Z., Chou A., Jiang Y., et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 2006, 281:13612-13619.
32. Monasterio A., Urdaci M.C., Pinchuk I.V., Lopez-Moratalla N., Martinez-Irujo J.J. Flavonoids induce apoptosis in human leukemia U937 cells through caspase- and caspase-calpain-dependent pathways. Nutr Cancer 2004, 50:90-100.
33. Chien C.S., Shen K.H., Huang J.S., Ko S.C., Shih Y.W. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 2010, 333:169-180.
34. Wilson W.J., Poellinger L. The dietary flavonoid quercetin modulates HIF-1 alpha activity in endothelial cells. Biochem Biophys Res Commun 2002, 293:446-450.
35. Welford R.W., Schlemminger I., McNeill L.A., Hewitson K.S., Schofield C.J. The selectivity and inhibition of AlkB. J Biol Chem 2003, 278:10157-10161.
36. Triantafyllou A., Liakos P., Tsakalof A., Chachami G., Paraskeva E., Molyvdas P.A., et al. The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 2007, 41:342-356.
37. Jeon H., Kim H., Choi D., Kim D., Park S.Y., Kim Y.J., et al. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol 2007, 71:1676-1684.
38. Park S.S., Bae I., Lee Y.J. Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. J Cell Biochem 2008, 103:1989-1998.
39. Jones D.T., Pugh C.W., Wigfield S., Stevens M.F., Harris A.L. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 2006, 12:5384-5394.
40. Niu G., Briggs J., Deng J., Ma Y., Lee H., Kortylewski M., et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 2008, 6:1099-1105.
41. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375:577-581.